Safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to biological therapies: a multicentre, double-blind, randomised, controlled, phase 2 trial

相似書籍

• Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study
  由: Roy Fleischmann, et al.
  出版: (2024-07-01)
• CFTR Rescue in Intestinal Organoids with GLPG/ABBV-2737, ABBV/GLPG-2222 and ABBV/GLPG-2451 Triple Therapy
  由: Eyleen de Poel, et al.
  出版: (2021-09-01)
• PB2224: ABBV-744 ALONE OR IN COMBINATION WITH RUXOLITINIB OR NAVITOCLAX IN PATIENTS WITH MYELOFIBROSIS: A PHASE 1B STUDY
  由: John Mascarenhas, et al.
  出版: (2023-08-01)
• Impact of upadacitinib or adalimumab as initial therapy on the achievement of 48-week treatment goals in patients with rheumatoid arthritis and inadequate response to methotrexate: Post hoc analysis of a phase 3 study
  由: Mysler, E, et al.
  出版: (2021)
• The American Thoracic Society’s Spirometric Criteria Alone is Inadequate in Asthma Diagnosis
  由: John A Gjevre, et al.
  出版: (2006-01-01)